These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 35358030)
1. Change in Lung Function after Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Do Not Forget Anatomy! Martin C; Regard L; Chassagnon G; Burgel PR Am J Respir Crit Care Med; 2022 Jun; 205(11):1365-1366. PubMed ID: 35358030 [No Abstract] [Full Text] [Related]
2. Elexacaftor/tezacaftor/ivacaftor can rescue pancreatic function in F508del homozygous children. Nathan N; Thouvenin G; Dubern B; Corvol H Pediatr Pulmonol; 2024 Mar; 59(3):788-790. PubMed ID: 38088210 [No Abstract] [Full Text] [Related]
3. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis. Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662 [No Abstract] [Full Text] [Related]
4. Questions and Answers? Depression Symptoms Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment for Cystic Fibrosis. Lee TWR; Duff AJA Am J Respir Crit Care Med; 2024 Feb; 209(3):239-241. PubMed ID: 38113403 [No Abstract] [Full Text] [Related]
5. Reply to Martin Nichols DP; Rowe SM Am J Respir Crit Care Med; 2022 Jun; 205(11):1366-1367. PubMed ID: 35358029 [No Abstract] [Full Text] [Related]
6. Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort. Bacon DR; Stapleton A; Goralski JL; Ebert CS; Thorp BD; Nouraie M; Shaffer AD; Senior BA; Lee SE; Zemke AC; Kimple AJ Int Forum Allergy Rhinol; 2022 Feb; 12(2):223-226. PubMed ID: 34709729 [No Abstract] [Full Text] [Related]
7. Elexacaftor/tezacaftor/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study. Salvatore D; Cimino G; Troiani P; Bignamini E; Esposito I; Leonetti G; Zanda M; Manunza D; Pepe A Pediatr Pulmonol; 2022 Sep; 57(9):2253-2256. PubMed ID: 35577767 [No Abstract] [Full Text] [Related]
8. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R; N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA; Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085 [TBL] [Abstract][Full Text] [Related]
10. Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis? Merrill TB; Tyes J; Woodard TD Laryngoscope; 2024 Feb; 134(2):501-503. PubMed ID: 37548273 [No Abstract] [Full Text] [Related]
11. Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis. Anderson A; McCoy L; Pettit RS; Wright BA; Lubsch L Pediatr Pulmonol; 2021 Dec; 56(12):4053-4054. PubMed ID: 34499822 [No Abstract] [Full Text] [Related]
12. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS; Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Advanced Cystic Fibrosis Lung Disease. Djavid AR; Thompson AE; Irace AL; Gusman E; Altman K; DiMango EA; Keating CL Ann Am Thorac Soc; 2021 Nov; 18(11):1924-1927. PubMed ID: 34000224 [No Abstract] [Full Text] [Related]
14. Triple Therapy for Cystic Fibrosis Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D; N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease. O'Shea KM; O'Carroll OM; Carroll C; Grogan B; Connolly A; O'Shaughnessy L; Nicholson TT; Gallagher CG; McKone EF Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33154033 [No Abstract] [Full Text] [Related]
16. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization? Terlizzi V J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487 [No Abstract] [Full Text] [Related]
17. Neuropsychiatric symptoms with elexacaftor/tezacaftor/ivacaftor: What does this mean for children? Pham H; Vandeleur M; Ranganathan S Pediatr Pulmonol; 2024 Mar; 59(3):537-539. PubMed ID: 37991124 [No Abstract] [Full Text] [Related]